[SCHEDULE 13G] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G filing: Bellevue Group AG and its wholly-owned subsidiary Bellevue Asset Management AG have disclosed a new beneficial ownership position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO).

• Stake size: 3,515,150 common shares, representing 6.1 % of the outstanding class as of the triggering date 06 / 01 / 2025.
• Voting & dispositive power: The reporting persons hold shared voting and dispositive power over the entire position; they report zero sole voting/dispositive power.
• Reporting entities: Bellevue Group AG (parent holding company, Switzerland) and Bellevue Asset Management AG (investment manager, Switzerland) filed jointly.
• Purpose: The securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control, as certified in Item 10.
• Form details: Filed 07 / 07 / 2025 under Rule 13d-1(b); CUSIP 00847X104; security class – common stock.

This disclosure introduces Bellevue as a >5 % institutional holder in Agios. While no strategic intentions are indicated, the filing may signal incremental institutional confidence and can affect perceptions of the shareholder base composition.

Positive

• Bellevue Group AG and subsidiary disclosed a 6.1 % beneficial stake (3.52 M shares), adding a sizeable institutional investor to Agios’ shareholder base.

Negative

• None.

Insights

Financial Analyst

TL;DR Bellevue reveals a 6.1 % AGIO stake; informative but not thesis-changing, signalling moderate institutional support.

Impact assessment: The appearance of a new 5 %+ holder is impactful from a governance and liquidity standpoint, yet carries no immediate operational implications. Bellevue’s shared-power structure suggests a typical asset-management holding rather than an activist position. Without intentions to seek control, the filing is primarily a transparency event.

Shareholder structure: Bellevue now ranks among Agios’ larger institutional investors, potentially improving float stability. However, because the position was accumulated by 06/01/2025, the market may already reflect this ownership.

Valuation & trading: 3.52 M shares roughly equate to 4–5 trading days of AGIO average volume, implying acquisition required deliberate accumulation. Still, absent disclosed purchase prices, it is impossible to gauge Bellevue’s cost basis or appetite for further buying.

Bottom line: Neutral to mildly positive; adds an experienced life-sciences investor to the register but offers no direct catalysts.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Agios Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00847X104

(CUSIP Number)

06/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00847X104

1

Names of Reporting Persons

Bellevue Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,515,150.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,515,150.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,515,150.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 00847X104

1

Names of Reporting Persons

Bellevue Asset Management AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,515,150.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,515,150.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,515,150.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Agios Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 88 Sidney Street Cambridge, MA, 02139
Item 2.
(a)	Name of person filing: Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG")
(b)	Address or principal business office or, if none, residence: Bellevue: Theaterstrasse 12, Zurich, Switzerland, CH-8001 BAM AG: Theaterstrasse 12, Zurich, Switzerland, CH-8001
(c)	Citizenship: Bellevue: Switzerland BAM AG: Switzerland
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 00847X104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Swiss Financial Market Supervisory Authority (FINMA)
Item 4.	Ownership
(a)	Amount beneficially owned: 3,515,150
(b)	Percent of class: 6.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,515,150
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,515,150
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bellevue Group AG

Signature:	/s/ Stefano Montalbano
Name/Title:	Stefano Montalbano/ Chief Financial Officer
Date:	07/07/2025

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	07/07/2025

Bellevue Asset Management AG

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	07/07/2025

Signature:	/s/ Ivo Betschart
Name/Title:	Ivo Betschart/Chief Finance & Controlling
Date:	07/07/2025

FAQ

Who filed the Schedule 13G for AGIO?

The filing was made jointly by Bellevue Group AG and Bellevue Asset Management AG.

How many Agios shares does Bellevue own?

Bellevue reports beneficial ownership of 3,515,150 common shares.

What percentage of Agios’ outstanding stock is represented?

The position equals 6.1 % of the company’s common shares.

Does Bellevue have sole or shared voting power?

Bellevue holds shared voting and dispositive power over all reported shares; it has no sole voting/dispositive power.

What is the CUSIP for Agios common stock?

The CUSIP referenced in the filing is 00847X104.

When was the Schedule 13G filed and what is the event date?

The filing date is 07 / 07 / 2025; the event triggering the filing occurred on 06 / 01 / 2025.

Did Bellevue state any intent to influence control of Agios?

No. The certification states the shares were acquired in the ordinary course and not to influence control.